Sanofi grabs a share of No­vavax's Covid vac­cine for $500M, eye­ing com­mer­cial­iza­tion, flu com­bi­na­tion

Sanofi is hand­ing No­vavax $500 mil­lion up­front to bring the biotech’s Covid-19 vac­cine in­to the fold, with dual goals of co-com­mer­cial­iz­ing the cur­rent vac­cine and de­vel­op­ing com­bo vac­cines that can tack­le both Covid and flu.

The deal al­so car­ries $700 mil­lion in de­vel­op­ment, reg­u­la­to­ry and launch mile­stones, mean­ing No­vavax can bag up to $1.2 bil­lion to­tal.

The French phar­ma gi­ant is al­so li­cens­ing No­vavax’s ad­ju­vant tech­nol­o­gy for use in oth­er vac­cine de­vel­op­ment — ear­mark­ing $200 mil­lion per prod­uct — and tak­ing a mi­nor­i­ty eq­ui­ty in­vest­ment in No­vavax of less than 5%. Shares of Mary­land-based No­vavax $NVAX, which have fall­en pre­cip­i­tous­ly from its pan­dem­ic peak, surged al­most 140% at one point in pre­mar­ket trad­ing Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER